Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02966340 · ClinicalTrials.gov registry record · Phase 1
Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment
A Phase 1 study of Alcoholism, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT02966340 is a Phase 1 study of Alcoholism that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 70 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02966340, a Phase 1 study of Alcoholism, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Prazosin
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2018-03-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02966340
The ClinicalTrials.gov registry entry for NCT02966340 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (81% lower). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02966340 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT02966340 about?
NCT02966340 is a clinical study titled "Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment". Double-blind, placebo-controlled, cross-over design study examining the effects of a norepinephrine alpha1 receptor antagonist (prazosin) on stress reactivity in a laboratory stressor task.
What is the current status of trial NCT02966340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2016-11-01. Estimated completion is 2018-03-12.
What conditions does trial NCT02966340 study?
This clinical trial studies the following conditions: Alcoholism.
What interventions are being tested in trial NCT02966340?
The interventions under investigation include: Placebo (DRUG), Prazosin (DRUG).
Who is sponsoring clinical trial NCT02966340?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02966340 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
N-acetylcysteine in Alcohol Dependence
COMPLETED · Phase 1
-
Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence
COMPLETED · Phase 1
-
A Novel Compound for Alcoholism Treatment
COMPLETED · Phase 1
-
Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
COMPLETED · Phase 1
-
GSK1521498 Alcohol Interaction Study
COMPLETED · Phase 1
-
Matching Genotypes and Serotonergic Medications for Alcoholism
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.